SABCS: Taxotere-Cytoxan Combo Shows Survival Advantage in Breast Cancer Adjuvant Therapy
12th Dec 2005, 16:20 GMT
SAN ANTONIO - Adjuvant breast-cancer chemotherapy with Taxotere (docetaxel) and Cytoxan (cyclophosphamide) delivers 33% better disease-free survival than the standard regimen of Adriamycin (doxorubicin) and Cytoxan, investigators here reported.
SABCS: Taxotere-Cytoxan Combo Shows Survival Advantage in Breast Cancer Adjuvant Therapy related news:
- Radiotherapy boosts survival rate for breast cancer patients: study — The Earth Times Online Newspaper
- Survival Benefit For Arimidex™ In Early Breast Cancer — Medical News Today RSS/XML Feed
- SABCS: Shorter Chemotherapy Regimen Plus Taxol Reduces Breast Cancer Recurrence — MedPage Today Hematology/Oncology
- Nonanthracycline TC Adjuvant Chemo Superior for Operable Breast Cancer — Medscape Medical News Headlines
- Aromatase inhibitor shows promise for breast cancer patients — The Cancer Blog
- Study Boosts Breast Cancer Survival — Sky News UK: Brings you closer to the news across Britain
- Radiotherapy aids breast cancer survival — MSNBC.com: Health
- San Antonio Breast Cancer Symposium Research Shows Hormone Replacement Therapy is No Help for Women Taking Tamoxifen — Mammography News from StratCenter.com
- Radiation 'key to cancer therapy' — BBC News | In Depth | Front page | UK Edition
- New Study Demonstrates Nonanthracycline Adjuvant Regimen TC Is Superior to Standard AC for Early Breast Cancer — Mammography News from StratCenter.com
Latest news from MedPage Today.com Latest Headlines:
- ACAAI: Rodent Exposure Linked to High Asthma Rates in Children
- ACR: Lupus Increases Pregnancy and Disease-Related Risks
- ACAAI: Rush Immunotherapy Provides Rapid Results Safely
- ACR: Small Weight Loss Equals Big Gains In Osteoarthritis Quality Of Life
- Care Found Lacking for Many With Obstructive Lung Disease
- AHA: Actos (pioglitazone) May Slow Progression of Atherosclerosis
- AHA: No Benefit from Late Revascularization After MI for Stable Patients
- AHA: When Stents Fail, Send in the Drug-Coated Balloons
- AHA: When Stents Fail, Send in the Drug-Coated Balloons
- Higher Hemoglobin Targets for Chronic Kidney Disease Linked to Heart Complications